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Obesity has become a global epidemic over the past few decades because of unhealthy dietary habits and reduced physical activity.
Hypertension and diabetes are quite common among obese individuals and there is a linear relationship between the degree of
obesity and these diseases. Lifestyle interventions like dietary modiﬁcations and regular exercise are still important and safe ﬁrst-
line measures for treatment. Recently, bariatric surgery has emerged as an important and very eﬀective treatment option for obese
individuals especially in those with comorbidities like hypertension and diabetes. Though there are few eﬀective drugs for the
managementof obesity, their eﬃcacy is only modest, and they should always be combined with lifestyle interventions for optimal
beneﬁt. In this paper we aim to outline the non-pharmacological measures for the management of hypertension and diabetes in
obesity.
1.Introduction
Hypertension, diabetes mellitus and obesity together form
24% of the global risk for mortality [1]. Cardiovascular
disorders related to these life-style diseases form the major
cause of morbidity and mortality among the suﬀerers
worldwide. Obesity has become a global epidemicin the past
few decades. Among the adult US population, 33.8% are
obese, and another 34.2% are overweight [2]. Obesity is a
risk factor for many diseases of which hypertension and type
2 diabetes mellitus are the most important.
Obese individuals (those with body mass index (BMI)
more than 30kg/m2) were found to have higher risk for
diabetes mellitus (age-adjusted odds ratio (OR) = 3.66)
and hypertension (age-adjusted OR = 3.72) compared to
those with normal body weight [3]. Overweight individuals
also had higher risk for diabetes and hypertension (age-
adjusted OR = 1.59 and 1.88, resp.) and those with morbid
obesity (BMI > 40kg/m2) had the highest risk (age-adjusted
OR = 7.37 and 6.38, resp.) [3]. As there is a signiﬁcant linear
relationship between body weight and these two diseases,
c o n t r o lo fe x c e s sb o d y w e i g h ti si m p o r t a n tf o rt h e i rp r e v e n -
tion and treatment.
Over the past few decades, a lot of eﬀective drugs have
been developed for the treatment of hypertension and dia-
betes. However, the pharmacotherapy of obesity is still not
verypromisingwithoutlifestylemodiﬁcationand/orsurgical
intervention. Therefore, we aim to discuss the treatment
options without drugs for management of hypertension and
diabetes in obesity through this paper.
2.Life-StyleInterventionsforTreatmentof
HypertensionandDiabetes inObesity
2.1. Exercise for the Obese Hypertensive. The role of physical
activity for treatment of hypertension is wellknown [4–6].
Aerobic exercise has shown to be associated with reduction2 International Journal of Hypertension
of systolic blood pressure (SBP) by 3.84mmHg and diastolic
blood pressure (DBP) by 2.58mm Hg in a meta-analysis
examining large data from 54 randomized controlled trials
[4]. More profound reduction of SBP (14.77mmHg) and
DBP (5.63mmHg) has been observed in a recent study
among obese patients after a 12-month regular exercise pro-
gram along with dietary changes [7]. Signiﬁcant reduction
in body weight and cardiometabolic parameters like insulin
resistance and hepatic fat also have been observed among the
participants in this study.
Regular exercise along with dietary modiﬁcations has
shown to be associated with signiﬁcantly greater reduction
in both SBP (4.5mmHg) and DBP (2.4mmHg) when com-
pared with dietary adjustments alone among hypertensive
patients [8]. Reduction in body weight was also higher
among the former group. Weight loss has been found to
be associated with a decrease in arterial stiﬀness [8, 9].
Better control of blood pressure among obese hypertensives
following weight loss may be partly due to the reduction in
arterial stiﬀness. Even minor reduction in the body weight
has been associated with better control of hypertension and
cardiovascular risk factors [10].
An average weight loss of 3.0kg through lifestyle inter-
ventions corresponded 2.5 years later with a 30% reduc-
tion in combined cardiovascular events, poorly controlled
blood pressure and the need to reinitiate antihypertensive
medications [11]. Reductions in total body and abdominal
fat, even without signiﬁcant weight loss achieved through
regular exercise, were found to be associated with improved
SBP, DBPand cardiovascular risk factors [12]. Diet, Exercise,
and Weight Loss Intervention Trial (DEW-IT) showed
that exercise-incorporated lifestyle interventions can result
in signiﬁcantly better BP control among patients taking
pharmacotherapy for hypertension [13].
2.2. Exercise for Diabetes in Obesity. Regular exercise im-
proves glycemic control in all forms of diabetes. Insulin
resistance is the major cause for hyperglycemia in obese
diabetics and physical activity is one of the best ways
to reduce insulin resistance [7, 14–16]. Physical activity
improves insulin resistance through various mechanisms.
Hepatic lipid accumulation is one of the primary mecha-
nisms that drive obesity-related insulin resistance and type 2
diabetes, and exercise can reduce the free fatty acid-induced
hepatic insulin resistance [14]. Reversal of hepatic insulin
resistance is related to the reduction in central adiposity
induced by exercise. Weight loss achieved by regular exercise
was found to improve hepatic insulin sensitivity better than
weight loss induced through calorie restriction [16]. Exercise
can also reduce hepatic glucose production and augment
insulin-mediated suppression of hepatic glucose output [14,
17].
Exercise increases skeletalmuscle glucoseuptakeand uti-
lization. This eﬀect is mediated by an increase in expression
of glucose transporter 4 (GLUT 4, an isoform of glucose
transporter) in skeletal muscle [18]. Exercise also induces
an increase in muscle insulin sensitivity [19]. Through
these adaptations in the muscle, physical activity improves
the peripheral glucose disposal and insulin resistance, and
augmentstheglycemiccontrolamongobeseindividualswith
diabetes.
Aerobic exercise has been demonstrated to improve the
insulin sensitivity and reduce the glycemic load, without any
signiﬁcant change in energy intake, among obese men and
women, and exercise may have a synergistic eﬀect to reduce
insulin resistance when combined with a low glycemic diet
[15]. Despite the absence of weight loss, moderate-intensity
exercise was associated with signiﬁcant reductions in visceral
obesity (an important determinant of insulin resistance)
among obese individuals with type 2 diabetes [20].
Look AHEAD (Action for Health and Diabetes) is a US
National Institutes of Health-funded long-term multicentric
clinical trial studying the eﬀect of an intensive lifestyle
interventiononcardiovascular disease (CVD)morbidityand
mortality in overweight/obese people with type 2 diabetes.
Weight loss achieved by exercise and dietary changes among
the intervention group resulted in better glycemic control
and CVD risk factors [21]. Reduced medication use and
lower therapeutic costs were the other beneﬁts observed
among this group after one year [22].
Diabetes Prevention Program (DPP) was a prospective
multi-centre randomized clinical trial examining the dia-
betes incidence in overweight/obese adults managed with
intensive lifestyle intervention or metformin or placebo.
Exercise-incorporatedlifestyle interventionreducedtheinci-
denceoftype2diabetesby58%andmetforminby31%when
compared with placebo after 2.8 years of follow up [23].
Decreased diabetes risk by lifestyle intervention observed in
the DPP trial was related to reductions of body weight, BMI,
and central adiposity [24]. Follow up data from the trial has
shown that the cumulative incidence of diabetes remained
lowest in the lifestyle intervention group even after 10 years
[25].
2.3. Dietary Measures for Hypertension Management in
Obesity. The Dietary Approaches to Stop Hypertension
(DASH)trialwas amulticenter,randomizedclinicaltrialthat
examined the eﬀects of dietary patterns on blood pressure.
This landmark study showed that a diet rich in fruits,
vegetables and low-fat diary products along with reduced
saturated and total fat lowered systolic blood pressure by
5.5mm Hg and diastolic blood pressure by 3.0mm Hg more
thana controldiet [26]. Foroverweight or obese persons, the
additionofexerciseandweightlosstotheDASHdietresulted
in even larger BP reductions and cardiac risk factors [8].
Dietary sodium restriction (to <3grams/day) is an im-
portant component of management of any patient with
hypertension. Overweight/obese hypertensives were found
to have higher salt sensitivity in observational studies [27,
28]. Obese subjects were also found to have an enhanced
rate of renal tubular sodium reabsorption [29]. Animal
studies showed that obesity is associated with salt retention
by the kidney through reduction of natriuresis (increased
clearance of atrial natriuretic peptide by adipose cells),
increased sympathetic activity and activation of renin an-
giotensin-aldosterone system (and high blood pressure asInternational Journal of Hypertension 3
ac o n s e q u e n c e )[ 30]. Hence, the beneﬁcial eﬀect of salt
restriction would be more profound among obese hyperten-
sives. A recent large population-based study reported from
China adds evidence to this concept [31].
A long-term dietary intervention trial with a nutrient-
fortiﬁed prepared meal plan (approximately 22% energy
from fat, 58% from carbohydrate and 20% from protein)
was found to be associated with better control of BP among
obese/overweight hypertensives than with the usual care
diet [32]. The dietary intervention group in this study also
achieved better weight loss and improved cardiovascular risk
factors. Combining a daily ﬁsh meal with a weight-loss diet
has an additive eﬀect on blood pressure among overweight
hypertensives [33].
A systematic review to determine the long-term eﬀects
of weight loss on hypertension through dietary interventions
versus pharmacologic treatment showed that the former
approach resulted in greater weight loss and BP reductions
than the latter [34]. The American Dietetic Association
recommends the application of medical nutrition therapy
(MNT) and lifestyle counseling as an integral component
of the medical treatment for management of speciﬁc disease
states and conditions (including hypertension and obesity)
and should be the initial step in the management of these
situations [35]. When pharmacotherapy becomes necessary
for control, MNT may complement or enhance its therapeu-
ticeﬀectiveness,thereby reducingoreliminating theneed for
multiple medications.
Excess alcohol consumption is well known to raise the
blood pressure in human beings. However, social drinking
may not be very hazardous. According to the European
Society of Hypertension and Cardiology recommendation,
alcohol consumption in hypertensive subjects who drink
alcohol should be limited to no more than 20 to 30gm of
ethanol per day for men and no more than 10 to 20gm for
women [36]. In obese hypertensives, low levels of drinking
may help to reduce calorie consumption and thus may
facilitate weight reduction.
Overall, weight reduction achieved through lifestyle
interventions like dietary modiﬁcation and regular exercise
programs (at least 30 minutes/day on most days) help
obese individuals with hypertension to obtain better BP
control and reduce complications related to uncontrolled
hypertension.
2.4. Dietary Measures to Treat Diabetes in Obesity. Nutri-
tional intervention is of paramount importance in pre-
venting diabetes, managing existing diabetes and prevent-
ing/slowing diabetic complications. Total calorie intake can
be distributed as follows in a type 2 diabetic: 45–65% of total
calorie intake as carbohydrate, 10–30% as proteins and less
than 30% as total fat (<7% saturated fat) with <300mg/day
of cholesterol [37]. Total calorie intake must be appropriate
to weight management goals of the individual. Macronu-
trient intake should be tailored according to the metabolic
status of the patient (e.g., lipid proﬁle). Similarly, there is
no evidence-based recommendation for generalization of
micronutrient supplements.
For obese diabetic, a weight losing diet containing either
low-carbohydrate or low-fat calorie-restricted diet may be
eﬀective in the short term (up to 1 year) [37]. Standard
weight loss diets provide 500–1,000 fewer calories than
estimatedtobenecessary forweightmaintenance.Upto10%
of weight loss can be achieved in 6 months with such diets.
Lipid proﬁles, renal function and protein intake (in those
with nephropathy) of patients on low-carbohydrate-diets
should be monitored and adjustments of hypoglycemic drug
therapy should be made to avoid the risk of hypoglycemia.
Maintenance of weight loss after one year usually depends
on the adherence to lifestyle interventions.
Intensive individualized dietary advice (according to the
nutritional recommendations of the European Association
fortheStudyofDiabetes)forsixmonthshasshown toreduce
H b A 1 cb y0 . 4 % ,b o d yw e i g h tb y1 . 3K g ,B M Ib y0 . 5k g / M 2
and waist circumference by 1.6cm when compared to con-
trols, among overweight/obese diabetics on optimal medical
treatment without adequate glycemic control [38].
Acarbohydrate intakeof 130grams/day is recommended
f o rp a t i e n t sa st h i sp r o v i d e sa d e q u a t eg l u c o s ef o rt h ec e n t r a l
nervous system, without reliance on glucose production
from ingested protein or fat, for its fuel needs [39]. Long-
term metabolic eﬀects of very-low-carbohydrate diets on
brain are unclear (though brain may function even on lower
carbohydrate diets) and such diets may result in imbalance
of energy, ﬁber, vitamins and minerals, and may not be
palatable.
3.BariatricSurgeryforManagementofObese
IndividualswithHypertensionand Diabetes
Few surgical procedures in the upper gastrointestinal tract,
collectively termed as bariatric surgery, have emerged as
important therapeutic options for management of obesity in
the recent years. They are classiﬁed as purely restrictive (lim-
iting thestomach volume)andprimarily malabsorptive [40].
Restrictive procedures commonly used now are laparoscopic
adjustable gastric banding and laparoscopic vertical sleeve
gastrectomy. The main malabsorptive procedure in use now
is Roux-en-Y gastric bypass.
Calorie restriction may be through three mechanisms in
bariatric surgery: (1) mechanical limiting of volume of the
gastric pouch and reduction of its outlet (2) modulation
of satiety by postprandial induction of neuro-hormonal
signals (e.g., peptide YY, an anorexiant) and (3) restriction
of calorie intake spontaneously adopted by patients to limit
the burden of postprandial dumping syndrome [41]. Weight
loss is achieved mainly through restriction of calorie intake.
Signiﬁcant weight loss following the surgery usually results
in improvement of diabetes and hypertension.
A recent meta-analysis that included 621 studies with
888 treatment arms and 135,246 patients has shown that the
weight loss overall was 38.5kg or 55.9% excess body weight
loss [42]. Overall, 78.1% of diabetic patients had complete
resolution and diabetes was improved or resolved in 86.6%
of patients. Improvement of diabetes usually occurs days
after surgery even before signiﬁcant weight loss is achieved.4 International Journal of Hypertension
Apart from calorie restriction obtained through the proce-
dure, improvement of insulin resistance and insulin sensitiv-
ity (mainly related to weight loss) also contributes to better
glycemic control among obese diabetic patients undergoing
bariatric surgery. Other proposed mechanisms are through
release of gut hormones like glucagon-like peptide-1 and
glucose-dependent insulinotropic polypeptide (the incretin
eﬀect) and increase in the beta-cell mass [41].
Hypertension was resolved in 61.7% and resolved or
improved in 78.5% of patients undergoing bariatric pro-
cedures [43]. The improvement in hypertension is mainly
related to weight loss. In general, one percent reduction in
bodyweightwilldecreasesystolicbloodpressureby1mmHg
and diastolic blood pressure by 2 mm Hg [43]. Reduction in
saltsensitivityandalterationofrenalhemodynamicsbrought
about by weight loss may be the contributing factors for
improvement of hypertension following bariatric surgery. A
14mmHg reduction in SBP and 12mm Hg reduction in
DBP was observed among obese hypertensives undergoing
bariatric surgery in a recent clinical trial [44]. Discontinua-
tion/ reduction of dose of antihypertensive medication can
be achieved in many patients following bariatric surgery.
Arecentstudyshowedthedistinctadvantagesofbariatric
surgery over lifestyle interventions for treatment of obesity
and related diseases like hypertension and diabetes [44].
The mean weight loss at one year was 30% and 8% in
the surgical and lifestyle intervention groups, respectively.
Remission rates of type 2 diabetes and hypertension were
signiﬁcantly higher in the surgery group than in the lifestyle
intervention group (70 versus 33% and 49 versus 23%).
Bariatric surgery is a relatively safe (perioperative mor-
tality rate 0.3%) procedure with only a few adverse con-
sequences (4.3%) [45] .T h em o s tf r e q u e n ta n ds e v e r e
a d v e r s ee v e n t si nt h ei m m e d i a t ep o s t p r o c e d u r ep e r i o da r e
anastomotic leaks, hemorrhage and thromboembolic events.
Long-term hazards are vitamin deﬁciencies, malnutrition,
osteoporosis, psychiatric disorders and a slightly higher risk
of accidental death [41, 46]. However, a Swedish study
showed signiﬁcantly reduced 10-year mortality risk with
bariatric surgery when compared to nonsurgical treatment
of obesity, making this treatment option a promise for many
[47].
The Scottish Intercollegiate Guidelines Network (SIGN)
recommends that bariatric surgery may be considered for
patients with all three of the following: (a) BMI of 35
or more, (b) one or more severe comorbidities that are
expected to have a meaningful clinical improvement with
weight reduction (e.g., severe mobility problems, arthritis,
type 2 diabetes), and (c) evidence of completion of a
structured weight management program that covered diet,
physical activity, and psychological and drug interventions
but did not result in signiﬁcant and sustained improvement
in co-morbidities [48]. The most recent Diabetes Surgery
Summit consensusconference recommends bariatric surgery
for type 2 diabetic patients with severe obesity (BMI >
35kg/m2) as well as in carefully selected, moderately obese
patients (BMI: 30–35kg/m2) who are inadequately con-
trolled by conventional medical and behavioral therapies
[49].
4.Conclusions
Weight loss achieved through lifestyle interventions like
dietary adjustments and regular physical activity are safe
and moderately eﬀective measures for management of
hypertension and diabetes in obesity. They also help to
reduce the treatment costs related to pharmacotherapy and
also to reduce the pill burden. Even when drug therapy
is considered, lifestyle interventions should continue, to
obtain the desired eﬀects of medications. Bariatric surgery
is more eﬀective than lifestyle interventions for treatment
and is remarkably safe in selected patient groups. These
non-pharmacological interventions should be the ﬁrst-
line management option and should also be combined
with pharmacotherapy for scientiﬁc treatment of these
diseases.
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